Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Clontech and Rubicon's RNA Library Prep Kit; BioNano Genomics' Irys; More

Premium

Clontech Laboratories and Rubicon Genomics have launched the SMARTer Universal Low Input RNA Library Prep Kit. The kit combines Rubicon's ThruPlex technology, which was designed for samples with very low inputs — between 50 picograms and 50 nanograms — with Clontech's SMARTer kits for RNA sequencing. The combined kit is available for sequencing on Illumina instruments.


BioNano Genomics has launched its Irys System for genome mapping in Europe. The system uses nanochannel array technology and can be used to analyze structural variation, finish genomes, and generate de novo physical maps of genomes. Additionally, the firm said it plans to launch IrysChip, which will be higher throughput, in the second half of the year.


Life Technologies has launched Oncomine Next Gen Sequencing Power Tools, an analytics offering for cancer researchers that consists of a suite of software tools to survey novel predicted driver mutations and gene fusions across all cancers and within two dozen specific cancers types, as well as explore simple summary analyses that integrate multiple types of gene and pathway aberrations with clinical data, according to the company.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.